Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR405838 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | SAR405838 and pimasertib in escalating doses |
| SAR405838 | EXPERIMENTAL | SAR405838 in escalating doses |
| Name | Type | Description |
|---|---|---|
| SAR405838 | DRUG | Pharmaceutical form:capsule Route of administration: oral |
| Pimasertib | DRUG | Pharmaceutical form: capsule Route of administration: oral |
Inclusion criteria: * Histologically or cytologically confirmed diagnosis of a solid tumor. * Presence of locally advanced or metastatic disease with at least one measurable lesion. * Ability to provide written informed consent. Evidence of a personally signed informed consent. Exclusion criteria:...
SAR405838 is an investigational small molecule being studied for the treatment of Neoplasm Malignant, a term for malignant tumors or cancer. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
SAR405838 is being developed by Sanofi, a multinational pharmaceutical company traded on the stock exchange under the ticker symbol SNY. The drug is currently in Phase 1 clinical trials for oncology indications.
SAR405838 is in Phase 1 clinical development. It has completed two Phase 1 trials, and it remains an investigational drug that has not received regulatory approval. Its safety and efficacy are still being evaluated in clinical studies.
SAR405838 has been studied in two completed Phase 1 trials. The first, NCT01636479, tested the safety of SAR405838 alone in 77 patients. The second, NCT01985191, evaluated SAR405838 combined with pimasertib in 26 cancer patients. Both trials enrolled adults with malignant neoplasms.
No, SAR405838 is not the same as pimasertib. They are distinct investigational drugs that have been studied together in a combination trial (NCT01985191). SAR405838 is a small molecule developed by Sanofi, while pimasertib is a separate agent used in the combination study.